OKYO · Insider Trading
OKYO Pharma Limited Ordinary Shares
Every open-market purchase and sale reported by OKYO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Gary S Jacob | CHIEF DEVELOPMENT OFFICER | Buy | +3,500 | +$4.90K |
| 2026-08-07 | Rajkumar V. Patil | Chief Scientific Officer | Buy | +3,363 | +$5.01K |
| 2026-08-07 | John P Brancaccio | Director | Buy | +5,000 | +$7.38K |
| 2026-08-07 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | Buy | +15,000 | +$23.09K |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy | +25,000 | +$35.00K |
| 2026-08-07 | Flavio Mantelli | CHIEF MEDICAL OFFICER | Buy | +20,000 | +$28.00K |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy | +22,500 | +$32.62K |
| 2026-08-07 | Gary S Jacob | CHIEF DEVELOPMENT OFFICER | Buy | +3,500 | +$4.90K |
| 2026-08-07 | Rajkumar V. Patil | Chief Scientific Officer | Buy | +3,363 | +$5.01K |
| 2026-08-07 | Flavio Mantelli | CHIEF MEDICAL OFFICER | Buy | +20,000 | +$28.00K |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy | +22,500 | +$32.62K |
| 2026-08-07 | Gabriele M Cerrone | Director | Buy | +25,000 | +$35.00K |
| 2026-08-07 | John P Brancaccio | Director | Buy | +5,000 | +$7.38K |
| 2026-08-07 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | Buy | +15,000 | +$23.09K |
| 2026-07-29 | Rajkumar V. Patil | Chief Scientific Officer | A | +3,363 | +$5.01K |
| 2026-07-23 | Gary S Jacob | CHIEF DEVELOPMENT OFFICER | A | +3,500 | +$4.90K |
| 2026-07-23 | Gabriele M Cerrone | Director | A | +22,500 | +$32.62K |
| 2026-07-23 | Robert John Dempsey | CHIEF EXECUTIVE OFFICER | A | +15,000 | +$23.09K |
| 2026-07-23 | John P Brancaccio | Director | A | +5,000 | +$7.38K |
| 2026-07-22 | Flavio Mantelli | CHIEF MEDICAL OFFICER | A | +20,000 | +$28.00K |
| 2026-07-21 | Gabriele M Cerrone | Director | A | +25,000 | +$35.00K |
| 2026-06-10 | Gabriele M Cerrone | Director | A | +300,000 | +$516.00K |
| 2026-06-10 | Willy Jules Simon | Director | A | +6,500 deriv. | — |
| 2026-06-10 | John P Brancaccio | Director | A | +6,500 deriv. | — |
| 2026-06-10 | Keeren Rameshchandra Shah | Chief Financial Officer | A | +40,000 deriv. | — |
| 2026-06-10 | Bernard Denoyer | Director | A | +3,500 deriv. | — |
| 2023-10-31 | Gabriele M Cerrone | Executive Chairman | J | +569,539 | +$854.31K |
| 2023-09-28 | John P Brancaccio | Director | Buy | +16,670 | +$25.00K |
| 2022-05-20 | Gabriele M Cerrone | Executive Chairman | Buy | +5,800,000 | +$440.80K |
| 2022-05-19 | Gabriele M Cerrone | Non-Executive Chairman | Buy | +37,500 | +$150.00K |
| 2022-05-19 | Gary S Jacob | Chief Executive Officer | Buy | +12,500 | +$50.00K |
| 2022-05-18 | Gabriele M Cerrone | Non-Executive Chairman | Buy | +25,000 | +$96.75K |
| 2022-05-18 | Gabriele M Cerrone | Non-Executive Chairman | Buy | +1,625,000 | +$96.69K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gabriele M Cerrone | Director | 10,851,416 | $15.63M |
| Gary S Jacob | CHIEF DEVELOPMENT OFFICER | 112,420 | $161.88K |
| John P Brancaccio | Director | 35,201 | $50.69K |
| Rajkumar V. Patil | Chief Scientific Officer | 20,030 | $28.84K |
| Flavio Mantelli | CHIEF MEDICAL OFFICER | 20,000 | $28.80K |
| Robert John Dempsey | CHIEF EXECUTIVE OFFICER | 15,000 | $21.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OKYO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.